Spyglass Pharma (SGP): Ra Capital Management, L.P. opened a new position $208M
Ra Capital Management, L.P. opened a new position in Spyglass Pharma, per its Q1 2026 13F.
- 8.02M
- Shares reported
- 2.2%
- Disclosed portfolio weight
- $208M
- Reported value
- Holdings as of
- Mar 31, 2026
- Filed
- May 15, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 26, 2026Company filing · Form 8-K · ResultsReported its results
- May 14, 2026Company filing · Form 8-K · ResultsReported its results
What came next
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Spyglass Pharma
OQRO holds no insider, Congress, fund or contract record for Spyglass Pharma dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SGP page.
How this filing works
Explore the data
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data